FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, particularly to a method for reducing glioblastoma cell proliferation. Said method involves delivery into glioblastoma cells of small interfering RNAs represented by sequences SEQ ID NO: 1 and SEQ ID NO: 2, in combination with chemotherapy with temozolomide TMZ.
EFFECT: invention provides suppression of glioblastoma cell proliferation, which is achieved by overcoming resistance to the classical chemotherapeutic agent temozolomide.
3 cl, 6 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| DOUBLE-STRANDED RNA CAPABLE OF REDUCING EXPRESSION OF MUTANT ALLELE C.607G>A OF HUMAN GNAO1 GENE | 2022 |
|
RU2816137C1 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| PREPARATIONS PROVIDING RNA-INTERFERENCE FOR GST-PI GENE MODULATION | 2015 |
|
RU2719185C2 |
| LINES OF ENGINEERED PRODUCER CELLS AND METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2823068C2 |
| OLIGONUCLEOTIDE SEQUENCES AIMED AT THE TRANSCRIPTION FACTOR TSC22D4, FOR TREATING INSULIN RESISTANCE | 2016 |
|
RU2723091C2 |
| OPTIMIZED STRAIN OF POLIOVIRUS TYPE 3 FOR THERAPY OF SOLID TUMOURS | 2023 |
|
RU2836222C1 |
| COMPOSITION BASED ON LITHIUM CITRATE AND MELATONIN WITH ANTI-GLIOBLASTOMA EFFECT | 2022 |
|
RU2787883C1 |
| METHOD FOR ANALYSING SOMATIC MUTATIONS IN IDH1 AND IDH2 GENES USING LNA-BLOCKING PCR AND HYBRIDISATION WITH BIOLOGICAL MICROCHIP | 2024 |
|
RU2839291C1 |
| USE OF ALPHAVIRUS IN PREPARATION OF ANTITUMOR DRUGS | 2015 |
|
RU2693938C2 |
